Making best practice, everyday practice

Login Register

Dapagliflozin improves outcomes in heart failure patients

In the DAPA-HF trial, SGLT-2i dapagliflozin added to optimal standard therapy in patients with HF with reduced ejection fraction, reduced the risk of worsening HF events, CV death, and improved symptoms.

Read below to complete the CPD questions Dapagliflozin improves outcomes in heart failure patients

Do you like this? Share with a colleague